Charles River Laboratories International, Inc.
345.37USD
+5.7100 (+1.68%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on CRL.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,004 | 996 | 994 | 1,005 | 1,032 | 984 | 1,003 | 1,010 |
| Cost of Revenue | — | — | — | — | — | — | — | 661 |
| Gross Profit | — | — | — | — | — | — | — | 349 |
| Operating Income | 120 | 120 | -283 | 134 | 100 | 75 | -168 | 117 |
| Net Income | -1 | -15 | -277 | 54 | 52 | 25 | -214 | 70 |
| EPS (Diluted) | -$0.03 | -$0.30 | -$5.56 | $1.10 | $1.06 | $0.50 | -$4.17 | $1.33 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)